Prosit Sole: chimeric proteins for rare disease

Prosit Sole aims to improve known therapeutic proteins, cytokine drugs through chimeras

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform.

The idea is to combine desirable structural features from different protein family members to generate libraries of candidate therapies with optimized potency, pharmacodynamics, shelf life and protein expression. Prosit Sole will deploy the libraries in functional screens, Director, Founder and CEO Hongyu Liu told BioCentury.

Liu highlighted two main obstacles to generating variants of known therapeutic proteins. Building in too many changes can create novel immunogenic T cell epitopes while minor alterations, such as single

Read the full 942 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers